Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

0.6023 -0.0285 (-4.52%)
Streaming Delayed Price Updated: 3:52 PM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 126,417
Open 0.6356
Bid (Size) 0.6023 (100)
Ask (Size) 0.6150 (2,000)
Prev. Close 0.6308
Today's Range 0.5900 - 0.6409
52wk Range 0.4000 - 2.110
Shares Outstanding 20,821,353
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Enters Binding Terms To Acquire CL-273 For EGFR-Mutant Lung Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
From Kairos Pharma, Ltd
Via Business Wire

Performance

YTD
-17.4%
-17.4%
1 Month
-5.9%
-5.9%
3 Month
-28.3%
-28.3%
6 Month
-67.4%
-67.4%
1 Year
-37.9%
-37.9%

More News

Read More
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets
Via Investor Brand Network
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
From Kairos Pharma, Ltd
Via Business Wire
TinyGemsBreaks – To Participate In DealFlow Discovery Conference
Via Investor Brand Network
News headline image
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives Clinical Trials Arena Research and Development Award for Advanced Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2025 Milestones and Clinical Progress in CEO Letter to Shareholders
Via Investor Brand Network
News headline image
Kairos Pharma Provides Shareholder Update
From Kairos Pharma Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Top movers in Friday's session ↗
Via Chartmill
News headline image
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV105 in Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Host KOL Event on Phase 2 ENV105 Prostate Cancer Trial
Via Investor Brand Network
News headline image
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire

Frequently Asked Questions

Is Kairos Pharma, Ltd. Common Stock publicly traded?
Yes, Kairos Pharma, Ltd. Common Stock is publicly traded.
What exchange does Kairos Pharma, Ltd. Common Stock trade on?
Kairos Pharma, Ltd. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Kairos Pharma, Ltd. Common Stock?
The ticker symbol for Kairos Pharma, Ltd. Common Stock is KAPA on the New York Stock Exchange
What is the current price of Kairos Pharma, Ltd. Common Stock?
The current price of Kairos Pharma, Ltd. Common Stock is 0.6023
When was Kairos Pharma, Ltd. Common Stock last traded?
The last trade of Kairos Pharma, Ltd. Common Stock was at 03/12/26 03:52 PM ET
What is the market capitalization of Kairos Pharma, Ltd. Common Stock?
The market capitalization of Kairos Pharma, Ltd. Common Stock is 12.54M
How many shares of Kairos Pharma, Ltd. Common Stock are outstanding?
Kairos Pharma, Ltd. Common Stock has 13M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.